Pediatrix Medical Group (NYSE:MD) Coverage Initiated by Analysts at Macquarie

Macquarie began coverage on shares of Pediatrix Medical Group (NYSE:MD) in a research report released on Monday, MarketBeat.com reports. The brokerage issued an outperform rating and a $18.00 target price on the stock.

Several other equities analysts also recently weighed in on MD. Jefferies Financial Group raised their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Mizuho raised their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, December 11th. Finally, Truist Financial upped their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $16.42.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $14.01 on Monday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $16.41. The firm has a market capitalization of $1.20 billion, a P/E ratio of -4.58, a PEG ratio of 2.00 and a beta of 1.57. The company’s fifty day moving average is $14.11 and its two-hundred day moving average is $10.90.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same quarter in the previous year, the firm earned $0.29 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. Analysts forecast that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently bought and sold shares of MD. nVerses Capital LLC purchased a new position in shares of Pediatrix Medical Group in the 2nd quarter worth about $31,000. Innealta Capital LLC purchased a new position in Pediatrix Medical Group in the second quarter valued at approximately $33,000. Quest Partners LLC lifted its position in Pediatrix Medical Group by 25.6% during the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after buying an additional 1,524 shares in the last quarter. Finally, Quarry LP grew its stake in Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after buying an additional 1,662 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.